Oxford Brain Health Clinical Trials Unit : All Pages

• Oxford Brain Health Clinical Trials Unit
• Copyright
• Privacy Statement
• Accessibility Statement
• Oxford Mosaic Accessibility Statement
• Oxford Mosaic Privacy Statement
• About the Oxford Brain Health Clinical Trials Unit
• Publications
• Oxford Brain Health Clinical Trials Unit Staff
• Collaborate
• Research
• News
• Celebrating International Clinical Trials Day
• Contact Us
• Interventional and Diagnostic Research
• Medical Technology and Devices
• Developmental Studies
• Patient and Public Involvement
• Trial Management
• Quality Assurance
• The Maudsley bipolar disorder project Clinical characteristics of bipolar disorder I in a Catchment area treatment sample
• The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder
• The Maudsley Bipolar Disorder Project: The effect of medication, family history and duration of illness on IQ and memory in bipolar I disorder.
• Prevalence of mental incapacity in medical inpatients and associated risk factors: cross-sectional study
• The inter-rater reliability of mental capacity assessments
• Demographic, structural and genetic predictors of late cognitive decline after penetrating head injury
• Focal brain damage protects against post-traumatic stress disorder in combat veterans
• In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)
• Invitation to join the OBHCTU Patient and Public Involvement group
• Job Opportunities at OBHCTU
• Events and Training
• Contact Us Form
• OBHCTU Training Courses
• Dr Vanessa Raymont
• Nyla Haque
• Fundamentals of Trial Management
• Fundamentals of Quality Assurance
• Natasha Sandle
• Exploring the Issue of Diversity in Clinical Research, Special Edition
• Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR
• Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia
• Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers
• Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer’s disease
• The Validity of the Alcohol-Use-Disorder-Identification-Test and a Novel Proxy Test in the Assessment of Alcohol Consumption in the Cognitively Impaired Elderly
• A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol
• A phase II trial of tideglusib in Alzheimer's disease
• Decision-making capacity for treatment in psychiatric and medical in-patients: cross-sectional, comparative study
• Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography
• Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans
• Prof John Geddes
• Jen Lawson
• Jack Quaddy
• Knowledge and Innovation Bulletin, September 2020
• Knowledge and Innovation Bulletin, November 2020
• Clinical Trials
• Knowledge and Innovation Bulletin January 2021
• Knowledge and Innovation Bulletin February 2021